SUMMARY Plasma concentrations of cyclic nucleotides (adenosine monophosphate (AMP) and guanosine monophosphate (GMP) were measured by an ultrasensitive radioimmunoassay in 138 patients with heart failure due to various causes. Measurements were related to the New York Heart Association classification of symptoms, plasma noradrenaline concentrations, and mean pulmonary artery pressures. Serial concentrations of cyclic AMP and GMP were also measured daily in four patients treated for acute left ventricular failure. Plasma concentrations of cycle AMP were related to the severity of the heart failure, plasma noradrenaline concentrations, and pulmonary artery pressures. Cyclic AMP concentrations fell rapidly after treatment of acute left ventricular failure. Plasma concentrations of cyclic GMP also depended on the severity of heart failure and the pulmonary artery pressure, and decreased sharply with treatment although remaining at a high value. The cyclic GMP concentrations were significantly higher in patients with mitral stenosis than in those with other types of heart failure.
It is well known that sympathetic nervous activity increases in patients with congestive heart failure. Chidsey et al reported that urinary excretion of noradrenaline was increased in heart failure.1 Studies by Thomas and Marks2 and ourselves3 showed that the plasma concentration of noradrenaline increased in patients with congestive heart failure, suggesting that the sympathetic nervous activity of these patients is increased. On the other hand, Eckberg et al found that the parasympathetic influence on sinoatrial node automaticity as determined by vagal blockade with atropine was reduced in patients with heart failure. 4 They also reported that baroceptor-induced slowing of the heart rate provoked by phenylephrine was appreciably reduced in patients with heart disease. 4 With cyclic adenosine monophosphate (AMP), which is the second messenger for beta adrenergic agents and many hormones, the plasma concentration appears to reflect the changes in tissue5 since the nucleotide in plasma is in a dynamic steady state relation with its intracellular pools.6 Cyclic guanosine monophosphate (GMP), like cyclic AMP, is present in plasma,7 and its_plasma concentration cyclic AMP Requests for reprints to Dr K Ogawa, 2nd Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan.
Accepted for publication 26 January 1984 could serve as an index for cholinergic activity.8 In the present study, therefore, the plasma concentrations of noradrenaline, cyclic AMP, and cyclic GMP were measured simultaneously in patients with congestive heart failure.
Patients and methods
Eighty five normal subjects (54 men and 31 women, mean age 47 years) and 138 patients with congestive heart failure were studied. The latter group comprised 41 patients with ischaemic heart disease, 40 with valvular heart disease, 13 with hypertensive heart disease, 13 A one way analysis of variance was used to determine any significant differences in the group means. If the analysis of variance indicated a significant difference, a two tail, paired or unpaired t test was applied when appropriate.14 Probabilities were considered significant at the 0*05 level. Regression lines were fitted by the method of least squares. All values were expressed as mean±standard error of mean (SEM).
Results

PLASMA CONCENTRATION OF CYCLIC NUCLEOTIDES
Normal subjects Mean plasma concentrations of cyclic AMP and cyclic GMP in 85 normal subjects were 17.5(0.42) nmol/l and 3-9(0.16) nmol/l respectively. Figure 1 shows the mean concentration of cyclic AMP in relation to age. The concentration in patients aged between 60 and 69 years was higher and that of those aged between 70 and 79 years lower than that of patients in the other age groups. The mean concentration of cyclic GMP for patients aged 60-90 years was higher and that of those aged 20-29 years lower than that of patients in the other age groups. There was no significant correlation between the concentration of cyclic AMP and age in normal subjects, but the concentration of cyclic GMP was weakly correlated with age in normal subjects (r=0.443, p<0-001) when those aged between 70 and 79 years were excluded.
Congestive heart failure Figure 2 shows the mean plasma concentrations of cyclic AMP and cyclic GMP in patients with congestive heart failure according to the severity (NYHA class) of their symptoms. Cyclic AMP concentrations were significantly higher in patients in class II, III, and IV than in the normal subjects (p<0-001) and in patients m classes III (p<U UIU) ana IV (p<U)U5) tman PLASMA NORADRENALINE CONCENTRATIONS in those in class II. Cyclic GMP concentrations were The concentration of plasma noradrenaline was meas-significantly higher in patients in all classes than in the ured by a sensitive radioenzymatic method by Henry normal subjects (p<0-001) and in those in classes II et all2 modified by Lake et al. 13 In this assay, norad-(p<0-05), III (p<0-001), and IV (p<0.005) than in renaline was N-methylated by phenylethanol-those in class I; the mean concentration in patients in amine-N-methyltransferase, purified from bovine class III (p<005) was also significantly higher than in adrenal medulla and 3H-S-adenosyl-l-methionine those in class II (Fig. 2) . (New England Nuclear) to form 3H-adrenaline, which -There, were no significant effects of conventional was selectively isolated and measured by liquid scintil-treatment with digitalis and diuretic agents on plasma lation spectrometry (Beckman LS-335). In this assay, cyclic AMP and cyclic GMP concentrations in the recovery of noradrenaline from alumina-with ace-patients with the same severity of congestive heart Ogawa, Shiozu, Mizuno, Ban with congestive heart failure was significantly correlated with plasma cyclic GMP concentrations (y) (y=0-26x+1-36, r=0-65, p<0-02) (Fig. 3b) .
SERIAL CHANGES OF CYCLIC NUCLEOTIDES AFTER ACUTE LEFT HEART FAILURE
Serial changes of cyclic nucleotides in four patients with acute left heart failure were measured. As shown in Fig. 4 , the plasma concentrations of cyclic AMP Fig. 4 Serial changes of cyclic nucleotide concentrations after acute left heart failure.
with congestive heart failure due to valvar heart disease was 23*48(l*26) nmol/l compared with 23.25(1-25) nmolI in those in whom it was due to ischaemic heart disease and 24.03(1.93) nmol/l in patients in whom it was due to hypertensive heart disease. These findings were significantly higher than those in normal subjects (p<0.001), but there was no significant difference among patient groups with con- 
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Fig. 5 Comparison of mean plasma concentrations of cyclic nucleotides in patients with mitral stenosis (n = 16) and other heart disease (n =21) (NYHA class II). gestive heart failure due to each type of heart disease.
The mean plasma concentration of cyclic GMP in patients with congestive heart failure due to valvar heart disease was 10.78(0-80) nmol/l compared with 10.99(1.05) nmol/l in those in whom it was due to ischaemic heart disease and 10.49(1.37) nmol/l in those in whom it was due to hypertensive heart disease. These findings were significantly higher than those in normal subjects, but there was no significant difference among patient groups with congestive heart failure due to each type of heart disease. There was also no significant difference among the other patient groups with congestive heart failure.
Mitral stenosis
The mean concentration of cyclic GMP in patients with congestive heart failure in class II due to mitral stenosis was 13 .35(1.78) nmol/l, which was significantly higher (p<0*01) than that in patients with other types of heart disease (7.87(1.09) nmol/l. The mean plasma concentration of cyclic AMP in patients with congestive heart failure in the same class of mitral stenosis was, however, 22*13(1.56) nmol/l, whereas that of the other heart diseases was 20*29(1*62) nmol/l (NS) (Fig. 5 ).
Discussion
Recent studies have shown that the plasma concentration of cylic AMP and cyclic GMP in experimental animals and human subjects increased sharply on the administration of hormones or neurotransmitters, reflecting increases in the intracellular cyclic nucleotides caused by each cyclase activation. '5 16 Tyramine causes the discharge of catecholamines from adrenergic neuronal terminals, and its injection into rats leads to a rapid but short lived increase in plasma concentrations of cyclic AMP.'7 Injection of cholinergic agents caused sharp increases in plasma cyclic GMP in fasted rats. 8 Ui et al reported that vigorous exercise significantly increased plasma cyclic AMP and cyclic GMP. '5 The increase in plasma cyclic AMP was abolished by propranolol and reduced by atropine, whereas the increase in plasma cyclic GMP was not affected by propranol but was abolished by atropine, which suggests that muscarinic receptors are involved. Adrenaline produced significant increases in plasma cyclic AMP that were associated with slight increases in plasma cyclic GMP. 18 Injection of insulin into healthy human subjects increases the plasma concentration of cyclic AMP, but there is little, if any, increase in plasma cyclic GMP after insulin injection. [19] [20] [21] It is well known that the administration of insulin induces hypoglycaemia and an increased secretion of adrenaline from the adrenal _medulla. Hypotension elicited by methacholine resulted in a Ogawa, Shiozu, Mizuno, Ban, Ito, Satake significant increase in plasma cyclic GMP associated with slight increases in plasma cyclic AMP.8 Although there is evidence that increased sympathetic activity increases plasma cyclic AMP and increased parasympathetic activity increases plasma cyclic GMP, factors other than autonomic activity affect tissue concentrations of cyclic AMP and GMP. A variety of polypeptide hormones other than insulin affects the concentrations of cyclic AMP in certain tissues, and non-hormonal factors such as acid base status22 and prostaglandins23 also have some effect. Similarly, tissue concentrations of cyclic GMP are known to be affected by prostaglandins,24 acid base changes,25 potassium,26 and angiotensin.'6 These factors, however, seemed to have little influence on the plasma concentration of the cyclic nucleotides in patients in this study since the plasma noradrenaline concentrations were significantly correlated with cyclic AMP concentrations in patients with congestive heart failure.
After acute myocardial infarction, the plasma cyclic AMP concentration in patients without complications was significantly increased on the first day.2728 The concentration in patients with complications was also significantly higher than in those without. 28 On the other hand, there was an increase in plasma cyclic GMP concentration, which remained raised until the eighth day after acute myocardial infarction. 28 In patients with essential hypertension, the plasma concentration of cyclic AMP was significantly higher in untreated patients, those treated with a diuretic agent, and those treated with propranolol than in normal subjects, but the plasma concentration of cyclic GMP was similar in normal subjects and untreated patients.2930 Plasma cyclic AMP concentrations decreased significantly, whereas those of cyclic GMP increased significantly after long term treatment with propranolol. 29 In the present study the increased concentration of cyclic nucleotides in patients with congestive heart failure is unlikely to have been due to the diminished urine output in these patients, since the half life of 3H-labelled cyclic GMP and cyclic AMP in human whole blood in vitro at 370C is 30-50 minutes6 and renal excretion accounts for only about 15% of the clearance of each of these nucleotides in man. 6 It is interesting that the plasma concentration of cyclic GMP increased in patients with mitral stenosis, placing a heavy burden on the left atrium. Stimulation of the dense parasympathetic nerves in the atrium may have been responsible for the increased plasma concentration of cyclic GMP in these patients. In our study, there was no significant effect of conventional treatment with digitalis and diuretic agents on the cyclic nucleotide concentrations in patients with congestive heart failure of the same severity. The reason Increased cyclic nucleotides in congestive heart failure for this may be that the plasma concentration of cyclic nucleotides in patients with congestive heart failure increases with the symptomatic severity of heart failure as well as with the increase in pulmonary artery pressure, which is an index of congestive heart failure.
In conclusion, the present findings show that plasma concentrations of cyclic AMP and cyclic GMP were significantly increased in patients with congestive heart failure. Mean pulmonary artery pressure was significantly correlated with plasma cyclic AMP as well as cyclic GMP concentrations in these patients. Furthermore, the plasma cyclic GMP concentration in patients with mitral stenosis was significantly increased compared with that in other types of heart failure.
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